324 related articles for article (PubMed ID: 16611275)
1. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.
Capanni M; Calella F; Biagini MR; Genise S; Raimondi L; Bedogni G; Svegliati-Baroni G; Sofi F; Milani S; Abbate R; Surrenti C; Casini A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1143-51. PubMed ID: 16611275
[TBL] [Abstract][Full Text] [Related]
2. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
Zhu FS; Liu S; Chen XM; Huang ZG; Zhang DW
World J Gastroenterol; 2008 Nov; 14(41):6395-400. PubMed ID: 19009658
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Parker HM; Johnson NA; Burdon CA; Cohn JS; O'Connor HT; George J
J Hepatol; 2012 Apr; 56(4):944-51. PubMed ID: 22023985
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
[TBL] [Abstract][Full Text] [Related]
5. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study.
Lee S; Jin Kim Y; Yong Jeon T; Hoi Kim H; Woo Oh S; Park Y; Soo Kim S
Scand J Gastroenterol; 2006 May; 41(5):566-72. PubMed ID: 16638699
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease.
Fenkci S; Rota S; Sabir N; Akdag B
Eur J Med Res; 2007 Feb; 12(2):68-73. PubMed ID: 17369120
[TBL] [Abstract][Full Text] [Related]
7. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.
Boyraz M; Pirgon Ö; Dündar B; Çekmez F; Hatipoğlu N
J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):121-7. PubMed ID: 26316434
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.
Lebensztejn DM; Wojtkowska M; Skiba E; Werpachowska I; Tobolczyk J; Kaczmarski M
Adv Med Sci; 2009; 54(2):177-82. PubMed ID: 20022856
[TBL] [Abstract][Full Text] [Related]
10. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.
Sofi F; Giangrandi I; Cesari F; Corsani I; Abbate R; Gensini GF; Casini A
Int J Food Sci Nutr; 2010 Dec; 61(8):792-802. PubMed ID: 20465434
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
12. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
Askari F; Rashidkhani B; Hekmatdoost A
Nutr Res; 2014 Feb; 34(2):143-8. PubMed ID: 24461315
[TBL] [Abstract][Full Text] [Related]
13. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes.
Petit JM; Guiu B; Duvillard L; Jooste V; Brindisi MC; Athias A; Bouillet B; Habchi M; Cottet V; Gambert P; Hillon P; Cercueil JP; Verges B
Clin Nutr; 2012 Aug; 31(4):520-5. PubMed ID: 22209679
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.
Cankurtaran M; Tayfur O; Yavuz BB; Geyik S; Akhan O; Arslan S
Acta Gastroenterol Belg; 2007; 70(3):253-9. PubMed ID: 18074733
[TBL] [Abstract][Full Text] [Related]
15. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study.
Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2012 Feb; 63(1):35-40. PubMed ID: 22460459
[TBL] [Abstract][Full Text] [Related]
16. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
[TBL] [Abstract][Full Text] [Related]
17. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.
Sangouni AA; Mohammad Hosseini Azar MR; Alizadeh M
Br J Nutr; 2020 Aug; 124(4):450-456. PubMed ID: 32312333
[TBL] [Abstract][Full Text] [Related]
18. Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial.
Cansanção K; Citelli M; Carvalho Leite N; López de Las Hazas MC; Dávalos A; Tavares do Carmo MDG; Peres WAF
Nutrients; 2020 Nov; 12(11):. PubMed ID: 33147705
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
20. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
